233 related articles for article (PubMed ID: 11313972)
1. The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3.
García-Cuéllar MP; Zilles O; Schreiner SA; Birke M; Winkler TH; Slany RK
Oncogene; 2001 Jan; 20(4):411-9. PubMed ID: 11313972
[TBL] [Abstract][Full Text] [Related]
2. ENL, the MLL fusion partner in t(11;19), binds to the c-Abl interactor protein 1 (ABI1) that is fused to MLL in t(10;11)+.
García-Cuéllar MP; Schreiner SA; Birke M; Hamacher M; Fey GH; Slany RK
Oncogene; 2000 Mar; 19(14):1744-51. PubMed ID: 10777208
[TBL] [Abstract][Full Text] [Related]
3. The polycomb protein MPc3 interacts with AF9, an MLL fusion partner in t(9;11)(p22;q23) acute leukemias.
Hemenway CS; de Erkenez AC; Gould GC
Oncogene; 2001 Jun; 20(29):3798-805. PubMed ID: 11439343
[TBL] [Abstract][Full Text] [Related]
4. The leukemogenic fusion of MLL with ENL creates a novel transcriptional transactivator.
Schreiner SA; García-Cuéllar MP; Fey GH; Slany RK
Leukemia; 1999 Oct; 13(10):1525-33. PubMed ID: 10516753
[TBL] [Abstract][Full Text] [Related]
5. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein.
Xia ZB; Anderson M; Diaz MO; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8342-7. PubMed ID: 12829790
[TBL] [Abstract][Full Text] [Related]
6. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.
Mueller D; Bach C; Zeisig D; Garcia-Cuellar MP; Monroe S; Sreekumar A; Zhou R; Nesvizhskii A; Chinnaiyan A; Hess JL; Slany RK
Blood; 2007 Dec; 110(13):4445-54. PubMed ID: 17855633
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX.
Slany RK; Lavau C; Cleary ML
Mol Cell Biol; 1998 Jan; 18(1):122-9. PubMed ID: 9418860
[TBL] [Abstract][Full Text] [Related]
8. The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin.
Zeisig DT; Bittner CB; Zeisig BB; García-Cuéllar MP; Hess JL; Slany RK
Oncogene; 2005 Aug; 24(35):5525-32. PubMed ID: 15856011
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of t(11;19) breakpoints in childhood acute leukemias.
Rubnitz JE; Behm FG; Curcio-Brint AM; Pinheiro RP; Carroll AJ; Raimondi SC; Shurtleff SA; Downing JR
Blood; 1996 Jun; 87(11):4804-8. PubMed ID: 8639852
[TBL] [Abstract][Full Text] [Related]
10. Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus.
Joh T; Yamamoto K; Kagami Y; Kakuda H; Sato T; Yamamoto T; Takahashi T; Ueda R; Kaibuchi K; Seto M
Oncogene; 1997 Oct; 15(14):1681-7. PubMed ID: 9349501
[TBL] [Abstract][Full Text] [Related]
11. Structure of AF3p21, a new member of mixed lineage leukemia (MLL) fusion partner proteins-implication for MLL-induced leukemogenesis.
Sano K
Leuk Lymphoma; 2001 Aug; 42(4):595-602. PubMed ID: 11697487
[TBL] [Abstract][Full Text] [Related]
12. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation.
Rubnitz JE; Camitta BM; Mahmoud H; Raimondi SC; Carroll AJ; Borowitz MJ; Shuster JJ; Link MP; Pullen DJ; Downing JR; Behm FG; Pui CH
J Clin Oncol; 1999 Jan; 17(1):191-6. PubMed ID: 10458233
[TBL] [Abstract][Full Text] [Related]
13. Identification of MLL and chimeric MLL gene products involved in 11q23 translocation and possible mechanisms of leukemogenesis by MLL truncation.
Joh T; Kagami Y; Yamamoto K; Segawa T; Takizawa J; Takahashi T; Ueda R; Seto M
Oncogene; 1996 Nov; 13(9):1945-53. PubMed ID: 8934541
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.
Ayton PM; Cleary ML
Oncogene; 2001 Sep; 20(40):5695-707. PubMed ID: 11607819
[TBL] [Abstract][Full Text] [Related]
15. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
16. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
[TBL] [Abstract][Full Text] [Related]
17. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia.
Thirman MJ; Levitan DA; Kobayashi H; Simon MC; Rowley JD
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12110-4. PubMed ID: 7991593
[TBL] [Abstract][Full Text] [Related]
18. Complex MLL rearrangement in a patient with T-cell acute lymphoblastic leukemia.
Chervinsky DS; Sait SN; Nowak NJ; Shows TB; Aplan PD
Genes Chromosomes Cancer; 1995 Sep; 14(1):76-84. PubMed ID: 8527389
[TBL] [Abstract][Full Text] [Related]
19. DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis.
Strissel PL; Strick R; Tomek RJ; Roe BA; Rowley JD; Zeleznik-Le NJ
Hum Mol Genet; 2000 Jul; 9(11):1671-9. PubMed ID: 10861294
[TBL] [Abstract][Full Text] [Related]
20. Novel SWI/SNF chromatin-remodeling complexes contain a mixed-lineage leukemia chromosomal translocation partner.
Nie Z; Yan Z; Chen EH; Sechi S; Ling C; Zhou S; Xue Y; Yang D; Murray D; Kanakubo E; Cleary ML; Wang W
Mol Cell Biol; 2003 Apr; 23(8):2942-52. PubMed ID: 12665591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
